Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
or

Ligand Pharm (LGND)

Ligand Pharm (LGND)
108.12 -1.57 (-1.43%) 13:08 ET [NASDAQ]
108.45 x 14 109.44 x 100
Realtime by (Cboe BZX)
108.45 x 14 109.44 x 100
Realtime - - (-) -
Quote Overview for Wed, Mar 26th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
108.07
Day High
111.52
Open 109.54
Previous Close 109.69 109.69
Volume 41,902 41,902
Avg Vol 138,162 138,162
Stochastic %K 46.60% 46.60%
Weighted Alpha +36.04 +36.04
5-Day Change +0.29 (+0.27%) +0.29 (+0.27%)
52-Week Range 67.72 - 129.90 67.72 - 129.90
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,112,080
  • Shares Outstanding, K 19,255
  • Annual Sales, $ 167,130 K
  • Annual Income, $ -4,030 K
  • EBIT $ 10 M
  • EBITDA $ 45 M
  • 60-Month Beta 1.12
  • Price/Sales 12.87
  • Price/Cash Flow 69.50
  • Price/Book 2.54

Options Overview Details

View History
  • Implied Volatility 42.01% ( +1.62%)
  • Historical Volatility 46.84%
  • IV Percentile 48%
  • IV Rank 42.27%
  • IV High 54.02% on 11/01/24
  • IV Low 33.22% on 05/09/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 9
  • Volume Avg (30-Day) 44
  • Put/Call OI Ratio 0.42
  • Today's Open Interest 381
  • Open Int (30-Day) 486

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.14
  • Number of Estimates 2
  • High Estimate 0.17
  • Low Estimate 0.10
  • Prior Year 0.80
  • Growth Rate Est. (year over year) -82.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
103.43 +4.73%
on 03/13/25
Period Open: 115.01
125.17 -13.46%
on 03/03/25
-6.69 (-5.82%)
since 02/26/25
3-Month
102.79 +5.38%
on 01/13/25
Period Open: 114.25
125.17 -13.46%
on 03/03/25
-5.93 (-5.19%)
since 12/26/24
52-Week
67.72 +59.95%
on 04/22/24
Period Open: 68.64
129.90 -16.61%
on 11/07/24
+39.68 (+57.81%)
since 03/26/24

Most Recent Stories

More News
Ligand to Participate in March Investor Conferences

LGND : 108.37 (-1.20%)
Ligand: Q4 Earnings Snapshot

Ligand: Q4 Earnings Snapshot

LGND : 108.37 (-1.20%)
Ligand Reports Fourth Quarter and Full Year 2024 Financial Results

LGND : 108.37 (-1.20%)
Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences

LGND : 108.37 (-1.20%)
Insider Sale: Director at $LGND (LGND) Sells 2,406 Shares

JOHN L LAMATTINA, a director at $LGND ($LGND), sold 2,406 shares of the company on 11-27-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 7.5% of their shares....

LGND : 108.37 (-1.20%)
Ligand: Q3 Earnings Snapshot

Ligand: Q3 Earnings Snapshot

LGND : 108.37 (-1.20%)
3 'Strong Buy' Small-Cap Stocks to Snag Now for a Soft Landing

Explore three small-cap stocks with 'Strong Buy' ratings that are poised for significant growth as economic conditions hint at a potential soft landing.

KNSA : 22.81 (-1.64%)
LGND : 108.37 (-1.20%)
SCI : 80.03 (+1.82%)
VBR : 190.85 (-0.38%)
VKTX : 26.07 (-6.83%)
Ligand: Q2 Earnings Snapshot

Ligand: Q2 Earnings Snapshot

LGND : 108.37 (-1.20%)
3 Magnificent Growth Stocks to Buy Hand Over Fist

Small-cap stocks could get a boost from the central bank's anticipated rate cuts in 2025. These three stocks may be a great way to get ahead of this catalyst.

LGND : 108.37 (-1.20%)
AGEN : 1.6100 (-3.59%)
CGC : 1.0350 (-5.91%)
CURLF : 0.8500 (-4.92%)
Ligand: Q1 Earnings Snapshot

Ligand: Q1 Earnings Snapshot

LGND : 108.37 (-1.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Ligand, being a biotechnology company, focuses on developing/acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure. Ligand's Captisol formulation technology has allowed it to enter into several licensing deals and generate royalties. Captisol is a well validated...

See More

Key Turning Points

3rd Resistance Point 114.86
2nd Resistance Point 113.70
1st Resistance Point 111.69
Last Price 108.37
1st Support Level 108.52
2nd Support Level 107.36
3rd Support Level 105.35

See More

52-Week High 129.90
Last Price 108.37
Fibonacci 61.8% 106.15
Fibonacci 50% 98.81
Fibonacci 38.2% 91.47
52-Week Low 67.72

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Precision Trading with Bollinger Bands: Identifying Breakouts & Reversals